SCYNEXIS, Inc. (SCYX) News
Track canonical SquawkNews coverage tagged to SCYX, SCYNEXIS, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
SCYX Surges 27%
SCYX rises 27%
EQUITY | Jul 31, 2026, 07:00 PM UTC
H
Watching SCYNEXIS; Shares Trading Higher, Hearing GSK Is Close To Relaunching BREXAFEMME With The Co, FDA Updates BREXAFEMME Label With Pedi
Watching SCYNEXIS; Shares Trading Higher, Hearing GSK Is Close To Relaunching BREXAFEMME With The Co, FDA Updates BREXAFEMME Label With Pediatric Use Information And Revised Patient Safety Guidance
REGULATION | Jul 31, 2026, 04:04 PM UTC
H
SCYX resumes trading, now +8%
SCYX trading resumes with 8% gain
EQUITY | Jul 31, 2026, 04:03 PM UTC
H
SCYX Halted on Downside Volatility
SCYX trading halted due to volatility
EQUITY | Jul 31, 2026, 03:58 PM UTC
L
SCYNEXIS Starts Phase 1 Trial Of SCY-770 Activator Of Two Dosing Regimens
SCYNEXIS, Inc. (NASDAQ: SCYX ), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation of a Phase 1 study of SCY-770, a first-in-class, potent and direct AMP
EQUITY | Jun 30, 2026, 12:02 PM UTC